Results 161 to 170 of about 8,212 (230)

Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
An investigation of the tandem Tudor domain (TTD) domain of UHRF1 identified and extensively characterized the local anesthetic hydroxyprocaine as a strong ligand capable of activating related genes such as p53 and also highlighted a new, potentially druggable intramolecular interaction between TTD and UBL.
Efstratios Tsakalidis, Mariangela Giannouli, Ifigeneia Akrani, Anthi Panara, Eleni Katalagarianou, Kyriaki Degaita, Maria Giahou, Konstantina Kyriakou, Maria Routsi, Panagiota Efstathia Nikolaou, Evangelia Tsitsou, Aggeliki Tsoka, Constantinos C. Vorgias, Emmanuel Mikros, Evangelos Gikas, Eleni K. Efthimiadou, Vassilios Myrianthopoulos   +16 more
wiley   +1 more source

Computational mapping of productive POI-E3 ligase conformations to guide de novo degrader design: application to WEE1 and PKMYT1 PROTACs. [PDF]

J Cheminform
Nassar H, Schmidt M, Ibrahim HS, Robaa D, Sippl W.   +4 more
europepmc   +1 more source

Native Mass Spectrometry Analysis of Cullin-RING Ubiquitin E3 Ligase Complexes in the Context of Targeted Protein Degradation. [PDF]

Anal Chem
Sternicki LM, Crowe C, Wieske LHE, Ciulli A, Poulsen SA.   +4 more
europepmc   +1 more source

Mapping Scientific Landscapes and Therapeutic Innovations of Targeted Protein Degradation: A Scientometric Review. [PDF]

Pharmaceutics
Li C, Wang X, He A, Bao T, Zhuang W, He C, Yang Y.   +6 more
europepmc   +1 more source

Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma. [PDF]

Mol Cancer Ther
Tigu AB, Ivancuta A, Tomuleasa C, Nistor M, Kegyes D, Cenariu D, Munteanu R, Buzoianu AD, Einsele H, Federico M, Kobold S, Gulei D, Ciechanover A.   +12 more
europepmc   +1 more source

Precision-Engineered PROTACs: Integrating Physical and Chemical Strategies for Targeted Cancer Therapy. [PDF]

Small
Yao H, Zhang Y, Zhao H, Liu M, Liu C, Wang P, Chen W, Guo Z, Xing D, Yang J, Li B, Wang C.   +11 more
europepmc   +1 more source

Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome <i>c</i>-Apaf-1 axis in cancer therapy. [PDF]

Oncoscience
Jemmerson R.
europepmc   +1 more source

Induced proximity-based therapeutics for advanced prostate cancer. [PDF]

NPJ Drug Discov
Ching J, Chau CH, Figg WD.
europepmc   +1 more source

Recent advances in hormone-based biopharmaceuticals for cancer therapy. [PDF]

J Egypt Natl Canc Inst
Sarifulnazwan SN, Mohd Tajuddin NAF, Mohd Nasaruddin SNN, Muhammad Mukmin NMI, Engku Abdul Malik ESNS, Taher M, Susanti D, Khotib J, Faiyazuddin M, Widodo RT, Haris MS, Budiman H.   +11 more
europepmc   +1 more source

Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation. [PDF]

Pharmaceutics
Amin A, Nawaz T, Oliveira Ferreira O, Santana de Oliveira M.   +3 more
europepmc   +1 more source